1.Legislation on the Relief of Adverse Drug Reactions-induced Harm
China Pharmacy 1991;0(05):-
OBJECTIVE: To explore the ways to evolve the current domestic legislation on the relief of adverse drug reactions(ADR)-induced harm.METHODS: Suggestions on the improvement of the existing related legal systems were put forward by analyzing the status quo of the current legal regulations on the relief of ADR-induced harm.RESULTS & CONCLUSIONS: The relief pattern,liability principle,the scope of paying and the time limit of lawsuit etc should be given into full consideration in the legislation on the relief of ADR-induced harm.
2.Discussion on the Draft of Chinese Medicine Act
Chinese Journal of Information on Traditional Chinese Medicine 2017;24(1):5-7
Publishment of the draft of Chinese Medicine Act shows that the legislative work for TCM has achieved substantial progress. But after careful analysis on the legislative bills, there are some controversial questions, such as integration of traditional Chinese and western medicine, the setting of Chinese medicine clinics, Chinese medicine personnel training, the prescription-based processing Chinese medicine decoction pieces and dispensing Chinese materiamedica preparations by medical institutions. These all need to be further perfected.
3.Status Quo and Defects of Legal Regulations on Adverse Drug Reactions
China Pharmacy 1991;0(04):-
OBJECTIVE:To explore the ways to consummate the current domestic legal regulations on adverse drug reactions(ADRs).METHODS:The status quo and the defects of the current legal regulations on ADRs were analyzed;and taking ADR damage relief systems adopted in some countries as reference,we put forward some suggestions on the improvement of the existing related legal regulations.RESULTS & CONCLUSIONS:The existing related legal regulations should be consummated as early as possible in respect of constitutive requirements of ADRs,legal obligation,identification system etc via suitable legislation channel so as to protect patients' rights.
4.Legal Protection of Subjects' Informed Consent in Clinical Drug Trials
China Pharmacy 2007;0(28):-
OBJECTIVE:To provide the reference for the improvement of GCP(good clinical practice)regulations and protection of subject's human rights.METHODS:The status quo of the protection of subject's right of informed consent and the elements for the right of informed consent and the existing problems in its practice in China were analyzed.RESULTS & CONCLUSIONS:China should further promote the legislation of clinical trials,reinforce the legal education of researchers,and emphasize the supervision on the illegal tort act.
5.Biomechanical study on the silk tissue engineered tendon
Xu TIAN ; Fujiang ZHANG ; Shilian KAN
International Journal of Biomedical Engineering 2010;33(1):40-43
Objective To investigate the biomechanics of the tissue engineered tendons which use the embryonic tendon cells as the seed-cells and the silk as the scaffolds. Methods Two groups were set up with one as the group with tenocytes and the other as the group without tenocytes. Tissue engineered tendons were taken out at 2-week, 4-week, 6-week, 8-week post-operation, with 20 samples per-group each time. The values of biomechanics were measured and analyzed using the software SPSS 13.0. Results The biomechanical properties of the tissue engineered tendons in the group with tenocytes were significantly better than those in the group without tenocytes (P<0.05). In the group with tenocytes, the vitodynamics results got better with the increase of implantation time (P<0.05) except for the results of 8-week post--operation(P>0.05). But in the group without tenocytes, only the results of that from 8-week post-operation were of significant significance (P<0.05). Conclusion The results presented in the current study demonstrated that silk could stick tenocytes well, hold the characteristics of great resistance to draw after adhesion of tenocytes, and formed the tissue engineered tendon gradually in chickens, suggesting its potential application in the treatment of the defect of tendon.
6.Experimental study of tissue engineered tendon combined with silk in repair of tendon defect
Xu TIAN ; Fujiang ZHANG ; Shilian KAN
Orthopedic Journal of China 2006;0(04):-
[Objective]To investigate the possibility of construction of tendon defect with allogeneic embryonic tenocyte combined with silk.[Method]Roman hens were randomly divided into 2 groups: construction with allogeneic tenocyte combined with silk as cell group,construction with silk alone as non-cell group.The pathology,vitodynamics and elongation were compared between 2 groups at 2,4,6,and 8 weeks postoperatively.[Result]Collagen production and vitodynamics in cell group were better than those in non-cell group significantly(P
9.Prevention of hepatic metastasis from colorectal cancer by immunotherapy after resection of colorectal cancer
Heping KAN ; Fuzhou TIAN ; Qingxian ZHOU ; Xiaobo LIU ; Xiaojun LI
Chinese Journal of General Surgery 2001;10(3):234-236
Objective To study the preventive effect of hepatic metastasis from colorectal cancer and the immune function influence on postoperative patients with colorectal cancer treated by TIL, rIL-2 and cyclophosphamide by portal vein infusion. Methods One hundred and twenty-four patients with advanced colorectal cancer (Dukes B and Dukes C stage) were randomly divided into immunotherapy group and control group. The control group were treated with 5-Fu and MMC by intravenous injection after resection of colorectal cancer. The immunotherapy group were treated with TIL, rIL-2 and cyclophosphamide by portal vein infusion after resection of the tumor, then with chemotherapy as the control group. All cases were followed-up for 3 years. Results Eight cases (12.3%) had hepatic metastases from colorectal cancer in the immunotherapy group, but nineteen cases (33.2%) in the control group. There was significant difference between the two groups (P>0.05). The NK, IL-2 activity and CD3, CD4, CD4/CD8 levels in peripheral blood of the immunotherapy group increased significantly after treatment (P<0.05). Conclusions The TIL, rIL-2 and cyclophosphamide treatment after resection of colorectal cancer is effective in improving antitumorgenic immune function, and preventing hepatic metastases.
10.A cohort study on the association between fasting plasma glucose level over 5.3 mmol/L and risks of abnormal glucose metabolism and cardiovascular diseases in the elderly
Mingxing ZHAO ; Fangfang KAN ; Fusheng FANG ; Hui TIAN
Chinese Journal of Internal Medicine 2016;55(5):340-344
Objective The aim of the study was to evaluate the association of fasting plasma glucose (FPG) level over 5.3 mmol/L to the development of abnormal glucose metabolism and cardiovascular diseases (CVD).Methods This was a retrospective cohort study with 1 064 non-diabetic subjects(980 males;84 females) aged 60 or over, who carried out annual health check-up in Chinese PLA General Hospital from May, 1996 to May, 2015.Based on the average FPG level of 3 years before enrollment, the subjects were divided into four groups : < 5.3 mmol/L, 5.3-< 5.6 mmol/L, 5.6-< 6.1 mmol/L and 6.1-< 7.0 mmol/L.Glucose metabolic changes, complications and mortality were follow-up until May, 2015.Results (1)The initial 3-year average FPG levels were (4.9 ±0.4) mmol/L in the total 1 064 subjects.Among them, 126 subjects developed diabetes mellitus (DM) and 144 subjects developed impaired glucose regulation (IGR) during the follow-up visits.The proportions of IGR and diabetes increased with the FPG levels (P < 0.05).The risk for developing IGR was significantly higher in subjects with FPG≥5.3 mmol/L than in those with FPG < 5.3 mmol/L (RR =3.08, 95% CI 2.02-4.81, P <0.01).The risk for incident DM was markedly increased in subjects with FPG ≥ 5.6 mmol/L than in those with FPG <5.6 mmol/L (RR =6.73, 95% CI 3.90-11.52, P <0.01);(2)The risk for CVD was eight folds higher in subjects with FPG ≥5.3 mmol/L than in subjects with FPG < 5.3 mmol/L (RR =8.42,95% CI 5.11-13.82, P < 0.05);(3) Survival analysis showed that the risk of death was 1.47 times higher in subjects with FPG ≥ 5.3 mmol/L than in subjects with FPG < 5.3 mmol/L after years of followed-up (RR=l.47, 95%CI 1.09-1.98, P=0.0127).Conclusion The risks for IGR, CVD and mortality are higher in the elderly with FPG ≥5.3 mmol/L, which highlights the importance for the disease prevention in elder people with FPG 5.3 mmol/L or more.